Zydus Lifesciences Limited — Updates, 30-01-2025: Press Release

Zydus Takeda Healthcare, a joint venture between Zydus Lifesciences and Takeda, marks a significant milestone with the 25th anniversary of its Vashi manufacturing plant. This facility has played a crucial role in supplying active pharmaceutical ingredients (APIs) and intermediates for Takeda's markets in Europe, Japan, Brazil, and Korea, establishing itself as a 100% export-oriented unit. Moving forward, Zydus Takeda plans to enhance the plant’s offerings by expanding the API product portfolio and investing in capabilities such as kilo lab facilities and renewable energy initiatives. This strategy aligns with Takeda’s commitment to net-zero emissions and aims at improving efficiency and reducing waste through digital automation. The partnership's success hinges on shared values, focusing on safety, quality, and sustainability, with both companies optimistic about future growth opportunities. Investors should watch closely as these developments may position Zydus Takeda as a pivotal player in the pharmaceutical manufacturing sector.